Ultra high platelet count might be a characteristic feature of chronic myeloid leukemia rather than essential thrombocythemia

Leukemia Research

Volumn 31, Issue 3, 2007, Pages 416-417

  Tefferi, Ayalew ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT; VON WILLEBRAND FACTOR;

ADULT; BONE MARROW BIOPSY; CASE REPORT; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; GENE MUTATION; HEMATOMA; HUMAN; LETTER; MALE; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; RADICULAR PAIN; THROMBOCYTE COUNT; THROMBOCYTHEMIA; THROMBOCYTOSIS; VON WILLEBRAND DISEASE;

ADULT; DIAGNOSIS, DIFFERENTIAL; HUMANS; LEUKEMIA, MYELOID, CHRONIC; MALE; PLATELET COUNT; THROMBOCYTHEMIA, HEMORRHAGIC; VON WILLEBRAND DISEASE;

EID: 33846068194     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2006.08.013     Document Type: Letter

References (15)

1. Pikman Y., Lee B.H., Mercher T., McDowell E., Ebert B.L., Gozo M., et al. MPLW515L is a novel somatic activating mutation in Myelofibrosis with Myeloid metaplasia. PLoS Med 3 (2006) e270
2. McCarthy L.J., Graves V.L., Eigen H., and McGuire W.A. Platelet apheresis for extreme thrombocytosis in an 11-year-old girl with CML. Transfus Med 1 (1991) 187-189
3. Alacacioglu I., Ozcan M.A., Piskin O., Demirkan F., Ozsan G.H., and Undar B. Chronic myeloid leukaemia associated with extreme thrombocytosis. Haema 8 (2005) 701-703
4. Mason Jr. J.E., DeVita V.T., and Canellos G.P. Thrombocytosis in chronic granulocytic leukemia: incidence and clinical significance. Blood 44 (1974) 483-487
5. Silver R.T. Anagrelide is effective in treating patients with hydroxyurea-resistant thrombocytosis in patients with chronic myeloid leukemia. Leukemia 19 (2005) 39-43
6. Spigel S.C., and Mooney L.R. Extreme thrombocytosis associated with malignancy. Cancer 39 (1977) 339-341
7. Harrison C.N., Campbell P.J., Buck G., Wheatley K., East C.L., Bareford D., et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 353 (2005) 33-45
8. Bellucci S., Janvier M., Tobelem G., Flandrin G., Charpak Y., Berger R., et al. Essential thrombocythemias. Clinical evolutionary and biological data. Cancer 58 (1986) 2440-2447
9. Besses C., Cervantes F., Pereira A., Florensa L., Sole F., Hernandez-Boluda J.C., et al. Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients. Leukemia 13 (1986) 150-154
10. Tefferi A., Fonseca R., Pereira D.L., and Hoagland H.C. A long-term retrospective study of young women with essential thrombocythemia. Mayo Clin Proc 76 (2001) 22-28
11. Budde U., Schaefer G., Mueller N., Egli H., Dent J., Ruggeri Z., et al. Acquired von Willebrand's disease in the myeloproliferative syndrome. Blood 64 (1984) 981-985
12. Fabris F., Casonato A., Grazia del Ben M., De Marco L., and Girolami A. Abnormalities of von Willebrand factor in myeloproliferative disease: a relationship with bleeding diathesis. Br J Haematol 63 (1986) 75-83
13. Budde U., Scharf R.E., Franke P., Hartmann-Budde K., Dent J., and Ruggeri Z.M. Elevated platelet count as a cause of abnormal von Willebrand factor multimer distribution in plasma. Blood 82 (1993) 1749-1757
14. Sanchez-Luceros A., Meschengieser S.S., Woods A.I., Blanco A.N., Kempfer A.C., Casais P., et al. Acquired von Willebrand factor abnormalities in myeloproliferative disorders and other hematologic diseases: a retrospective analysis by a single institution. Haematologica 87 (2002) 264-270
15. van Genderen P.J., van Vliet H.H., Prins F.J., van de Moesdijk D., van Strik R., Zijlstra F.J., et al. Excessive prolongation of the bleeding time by aspirin in essential thrombocythemia is related to a decrease of large von Willebrand factor multimers in plasma. Ann Hematol 75 (1997) 215-220